Unknown

Dataset Information

0

Individualized therapy for persistent asthma in young children.


ABSTRACT: BACKGROUND:Phenotypic presentations in young children with asthma are varied and might contribute to differential responses to asthma controller medications. METHODS:The Individualized Therapy for Asthma in Toddlers study was a multicenter, randomized, double-blind, double-dummy clinical trial in children aged 12 to 59 months (n = 300) with asthma necessitating treatment with daily controller (Step 2) therapy. Participants completed a 2- to 8-week run-in period followed by 3 crossover periods with daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS treatment coadministered with albuterol. The primary outcome was differential response to asthma medication based on a composite measure of asthma control. The primary analysis involved 2 stages: determination of differential response and assessment of whether 3 prespecified features (aeroallergen sensitization, previous exacerbations, and sex) predicted a differential response. RESULTS:Seventy-four percent (170/230) of children with analyzable data had a differential response to the 3 treatment strategies. Within differential responders, the probability of best response was highest for a daily ICS and was predicted by aeroallergen sensitization but not exacerbation history or sex. The probability of best response to daily ICS was further increased in children with both aeroallergen sensitization and blood eosinophil counts of 300/?L or greater. In these children daily ICS use was associated with more asthma control days and fewer exacerbations compared with the other treatments. CONCLUSIONS:In young children with asthma necessitating Step 2 treatment, phenotyping with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment selection and identifies children with a high exacerbation probability for whom treatment with a daily ICS is beneficial despite possible risks of growth suppression.

SUBMITTER: Fitzpatrick AM 

PROVIDER: S-EPMC5148729 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Individualized therapy for persistent asthma in young children.

Fitzpatrick Anne M AM   Jackson Daniel J DJ   Mauger David T DT   Boehmer Susan J SJ   Phipatanakul Wanda W   Sheehan William J WJ   Moy James N JN   Paul Ian M IM   Bacharier Leonard B LB   Cabana Michael D MD   Covar Ronina R   Holguin Fernando F   Lemanske Robert F RF   Martinez Fernando D FD   Pongracic Jacqueline A JA   Beigelman Avraham A   Baxi Sachin N SN   Benson Mindy M   Blake Kathryn K   Chmiel James F JF   Daines Cori L CL   Daines Michael O MO   Gaffin Jonathan M JM   Gentile Deborah Ann DA   Gower W Adam WA   Israel Elliot E   Kumar Harsha Vardhan HV   Lang Jason E JE   Lazarus Stephen C SC   Lima John J JJ   Ly Ngoc N   Marbin Jyothi J   Morgan Wayne W   Myers Ross E RE   Olin J Tod JT   Peters Stephen P SP   Raissy Hengameh H HH   Robison Rachel G RG   Ross Kristie K   Sorkness Christine A CA   Thyne Shannon M SM   Szefler Stanley J SJ  

The Journal of allergy and clinical immunology 20161021 6


<h4>Background</h4>Phenotypic presentations in young children with asthma are varied and might contribute to differential responses to asthma controller medications.<h4>Methods</h4>The Individualized Therapy for Asthma in Toddlers study was a multicenter, randomized, double-blind, double-dummy clinical trial in children aged 12 to 59 months (n = 300) with asthma necessitating treatment with daily controller (Step 2) therapy. Participants completed a 2- to 8-week run-in period followed by 3 cross  ...[more]

Similar Datasets

| S-EPMC5085065 | biostudies-literature
| S-EPMC8676065 | biostudies-literature
| S-EPMC6504569 | biostudies-literature
| S-EPMC5610524 | biostudies-literature
| S-EPMC3332210 | biostudies-literature
| S-EPMC6070097 | biostudies-literature
| S-EPMC6339656 | biostudies-other
| S-EPMC4074435 | biostudies-literature